Thierry Mauvernay
InvestorPresident, Delegate of the Board, Debiopharm International SA at Debiopharm Innovation Fund
About
President of Après-demain, the parent holding company of Debiopharm, and chairman of the investment committee of the Debiopharm Innovation Fund. He previously worked as an entrepreneur in the international cosmetics industry and holds a Master of Science in Economics and Marketing and an MBA.
Colleagues at Debiopharm Innovation Fund
Angela Zubel
Chief Development Officer, Research & Development at Debiopharm Innovation Fund
Bertrand Ducrey
Chief Executive Officer, Debiopharm International & Senior Vice-Chairman, Debiopharm at Debiopharm Innovation Fund
Cedric Odje
Investment Associate at Debiopharm Innovation Fund
Chris Thomas
Director, Investments at Wollemi Capital
David Shin
Investor at Dash Fund
Dawid Książczak
Chief Legal Officer at McWin Capital Partners
Frédéric Lévy
Chief Scientific Officer, Search & Evaluation and Scientific Innovation at Debiopharm Innovation Fund
Kavita Patel
Principal at Muus Climate Partners
Frequently asked questions
- Who is Thierry Mauvernay?
- President of Après-demain, the parent holding company of Debiopharm, and chairman of the investment committee of the Debiopharm Innovation Fund. He previously worked as an entrepreneur in the international cosmetics industry and holds a Master of Science in Economics and Marketing and an MBA.
- Where does Thierry Mauvernay work?
- Thierry Mauvernay is President, Delegate of the Board, Debiopharm International SA at Debiopharm Innovation Fund.